The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1333
ISSUE1333
March 8, 2010
Rosiglitazone (Avandia) Revisited
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Rosiglitazone (Avandia) Revisited
March 8, 2010 (Issue: 1333)
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.